Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ARCT NASDAQ:FBIO NASDAQ:NATR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.87$4.40$3.08▼$5.10$962.02M0.622.44 million shs2.60 million shsARCTArcturus Therapeutics$7.28$7.60$5.85▼$24.17$206.90M2.37426,211 shs1.90 million shsFBIOFortress Biotech$3.04$2.69$1.77▼$4.53$100.99M1.21489,392 shs332,537 shsNATRNature's Sunshine Products$21.47$22.17$12.97▼$28.14$377.44M0.87130,786 shs100,214 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+6.68%+14.59%+9.19%+50.54%ARCTArcturus Therapeutics0.00%+5.81%-0.27%-11.44%-46.61%FBIOFortress Biotech0.00%+10.75%+14.72%+21.12%+59.25%NATRNature's Sunshine Products0.00%+2.14%+8.49%-12.72%+37.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.87$4.40$3.08▼$5.10$962.02M0.622.44 million shs2.60 million shsARCTArcturus Therapeutics$7.28$7.60$5.85▼$24.17$206.90M2.37426,211 shs1.90 million shsFBIOFortress Biotech$3.04$2.69$1.77▼$4.53$100.99M1.21489,392 shs332,537 shsNATRNature's Sunshine Products$21.47$22.17$12.97▼$28.14$377.44M0.87130,786 shs100,214 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+6.68%+14.59%+9.19%+50.54%ARCTArcturus Therapeutics0.00%+5.81%-0.27%-11.44%-46.61%FBIOFortress Biotech0.00%+10.75%+14.72%+21.12%+59.25%NATRNature's Sunshine Products0.00%+2.14%+8.49%-12.72%+37.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.002.67% UpsideARCTArcturus Therapeutics 2.64Moderate Buy$24.25233.10% UpsideFBIOFortress Biotech 2.25Hold$17.00459.21% UpsideNATRNature's Sunshine Products 2.67Moderate Buy$35.0063.02% UpsideCurrent Analyst Ratings BreakdownLatest FBIO, ABUS, ARCT, and NATR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)5/26/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/18/2026FBIOFortress Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/11/2026NATRNature's Sunshine Products Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/11/2026NATRNature's Sunshine Products DA DavidsonSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$33.005/8/2026NATRNature's Sunshine Products Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$37.004/21/2026ARCTArcturus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$14.08M68.33N/AN/A$0.40 per share12.18ARCTArcturus Therapeutics$82.03M2.52N/AN/A$7.53 per share0.97FBIOFortress Biotech$63.26M1.60N/AN/A$2.00 per share1.52NATRNature's Sunshine Products$480.14M0.79$2.17 per share9.88$9.23 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.87N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)ARCTArcturus Therapeutics-$65.78M-$2.81N/AN/AN/A-143.80%-36.55%-28.40%8/10/2026 (Estimated)FBIOFortress Biotech$6.82M$3.170.96N/AN/A193.12%109.66%45.56%8/13/2026 (Estimated)NATRNature's Sunshine Products$19.52M$1.1019.52N/AN/A4.06%14.67%9.27%7/30/2026 (Estimated)Latest FBIO, ABUS, ARCT, and NATR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026NATRNature's Sunshine Products$0.27N/AN/AN/A$123.70 millionN/A5/14/2026Q1 2026FBIOFortress Biotech-$0.22$2.82+$3.04$2.82$16.34 million$16.04 million5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/8/2026Q1 2026ARCTArcturus Therapeutics-$1.0320-$0.95+$0.0820-$0.95$6.30 million$2.06 million5/7/2026Q1 2026NATRNature's Sunshine Products$0.2050$0.30+$0.0950$0.29$122.15 million$122.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/ANATRNature's Sunshine ProductsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26ARCTArcturus TherapeuticsN/A6.316.31FBIOFortress Biotech0.182.862.77NATRNature's Sunshine ProductsN/A2.501.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ARCTArcturus Therapeutics94.54%FBIOFortress Biotech96.51%NATRNature's Sunshine Products79.40%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%ARCTArcturus Therapeutics17.80%FBIOFortress Biotech28.50%NATRNature's Sunshine Products3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableFBIOFortress Biotech17033.22 million23.75 millionOptionableNATRNature's Sunshine Products85017.58 million17.04 millionOptionableFBIO, ABUS, ARCT, and NATR HeadlinesRecent News About These CompaniesNature's Sunshine Products, Inc. (NASDAQ:NATR) Sees Large Growth in Short InterestJuly 4 at 4:21 AM | americanbankingnews.comNature's Sunshine Products, Inc. (NASDAQ:NATR) Short Interest UpdateJuly 2, 2026 | marketbeat.comPersonal care stocks Q1 in review: Nature's Sunshine (NASDAQ:NATR) vs peersJuly 1, 2026 | msn.comNature's Sunshine Products : NATRJune 25, 2026 | 247wallst.comNature's Sunshine Products (NASDAQ:NATR) Stock Passes Below Two Hundred Day Moving Average - What's Next?June 25, 2026 | americanbankingnews.comNature's Sunshine Products (NASDAQ:NATR) EVP Sells $41,360.00 in StockJune 16, 2026 | insidertrades.comBryant Yates Sells 11,968 Shares of Nature's Sunshine Products (NASDAQ:NATR) StockJune 12, 2026 | insidertrades.comNature's Sunshine: A Herbal Engine With Digital Roots Starting To ShowJune 8, 2026 | seekingalpha.comHow The Story Around Nature’s Sunshine (NATR) Is Shifting After Q4 And New Analyst TargetsJune 8, 2026 | finance.yahoo.comDaniel Norman Sells 9,713 Shares of Nature's Sunshine Products (NASDAQ:NATR) StockJune 4, 2026 | insidertrades.comHow The Nature’s Sunshine (NATR) Narrative Is Shifting With Q4 Beats And Digital GrowthMay 25, 2026 | finance.yahoo.comInsider Selling: Nature's Sunshine Products (NASDAQ:NATR) EVP Sells 12,015 Shares of StockMay 23, 2026 | insidertrades.comNatures Sunshine Products Stock Dividends | NASDAQ:NATR | BenzingaMay 13, 2026 | benzinga.comNATR Q1 Deep Dive: Digital Channel Expansion and Margin Gains Shape OutlookMay 11, 2026 | finance.yahoo.comNature's Sunshine Products, Inc. Just Beat EPS By 41%: Here's What Analysts Think Will Happen NextMay 11, 2026 | finance.yahoo.comNature’s Sunshine Products, Inc. (NASDAQ:NATR) Q1 2026 Earnings Call TranscriptMay 8, 2026 | insidermonkey.comNature's Sunshine’s (NASDAQ:NATR) Q1 CY2026: Beats On RevenueMay 8, 2026 | finance.yahoo.comNature's Sunshine targets $1B sales and 15% EBITDA margin as it reiterates 2026 $500M-$515M outlookMay 8, 2026 | msn.comNature’s Sunshine Shareholders Approve 2026 Stock Incentive PlanMay 7, 2026 | tipranks.comNature's Sunshine Products, Inc. (NATR) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comNature's Sunshine Products (NATR) Stock Rises on Q1 2026 EarningsMay 7, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFBIO, ABUS, ARCT, and NATR Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.87 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.87 0.00 (-0.04%) As of 07:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Arcturus Therapeutics NASDAQ:ARCT$7.28 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$7.44 +0.16 (+2.20%) As of 07:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Fortress Biotech NASDAQ:FBIO$3.04 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.02 -0.02 (-0.82%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Nature's Sunshine Products NASDAQ:NATR$21.47 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$21.68 +0.21 (+0.95%) As of 07:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
